We have just fallen below the 20 SMA which was at $1.41.
Go back to the Yahoo interactive chart and put the 20 SMA on the 6 month YMI chart. Now study the points that the stock crossed to the upside and again to the downside. Crossing the 20 SMA is your buy and sell points. I have been very happy with this strategy on most all my investments.
July 15, 09 to Sept. 23, 09 = $1.07 profit Dec. 15, 09 to Jan. 26, 2010 = .37¢ profit Apr. 1, 2010 to Apr. 27th, 2010 = .22¢ profit
So, in three trades during the last year there is a profit of $1.66 pps on just using the 20 SMA as your trading strategy. Obviously, the ultimate peeks have been higher than the sell points, and you do leave some money on the table with this strategy - unless of course you call the tops. You will also notice that the next tallest peek, on the back side (of the original high), never gets above the original high. This sends up red flags about a potential reversal and shows the stock has run out of steam. It also helps you possibly get out a little earlier and make a few pennies more.
Just sharing here - everyone has their own strategy.
YMI - There pipeline is far too long to even try to post. We are talking 30+ clinical trials. Most of these are based on Nimotuzumab, which is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. This company is very global!
They recently raised $17 million dollars, which seems very needed given their vast network of trials. They recently had 2 presentations at the AACR on the Nimo drug(Source).
They have several presentations at ASCO. There could be more than what is below, it is just hard to find these. After a little digging, we have:
"#5530: An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study.
#5565: Results from a pilot study of nimotuzumab with concurrent chemoradiation in patients with locally advanced squamous cell carcinoma of head and neck."